Transposagen licenses piggyBac™ technology to DNA2.0
Transposagen licenses piggyBac™ technology to DNA2.0
The World’s Fastest Synthetic Gene Synthesis Service is Now Available in the World’s Most Efficient Non-viral Genetic Modification System
Lexington, Kentucky December 14, 2011- Transposagen Biopharmaceuticals Inc. (Transposagen) announced today that it has entered into a non-exclusive licensing agreement with gene synthesis company DNA2.0. The highly efficient DNA-2-GO™ gene synthesis process can now be used to generate genes which are immediately usable in piggyBac™ expression vectors. PiggyBacTM is the cheapest and most efficient method for gene transduction in mammalian cells. Other advantages of using the piggyBac™ DNA Modification System include reversible genetic modification, unlimited insertion size, copy number control and rapid insertion site characterization. Applications of this system range from stem cell research to protein production and cell line engineering. “DNA2.0’s expertise in DNA synthesis combined with the utility of the piggyBac™ DNA Modification System will open up many possibilities in biomedical research, as well as industrial protein production”, said Eric Ostertag, President and CEO of Transposagen.
About Transposagen Biopharmaceuticals:
Transposagen Biopharmaceuticals, Inc., a Lexington, KY-based company, is the worldwide leader in the creation of unique genetically modified rat models. The company’s signature products, TKOTM Knockout Rat Models and TGEMTM Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models and custom knockout rat models to customer specifications. For more information or to request a custom rat model, visit www.transposagenbio.com.
About DNA2.0
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 provides an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.